BR112014010957A2 - substituted pyrazolyl-based urea and carboxamide derivatives carrying a moiety of phenyl substituted by a group containing n as vanyloid receptor ligands - Google Patents

substituted pyrazolyl-based urea and carboxamide derivatives carrying a moiety of phenyl substituted by a group containing n as vanyloid receptor ligands

Info

Publication number
BR112014010957A2
BR112014010957A2 BR112014010957A BR112014010957A BR112014010957A2 BR 112014010957 A2 BR112014010957 A2 BR 112014010957A2 BR 112014010957 A BR112014010957 A BR 112014010957A BR 112014010957 A BR112014010957 A BR 112014010957A BR 112014010957 A2 BR112014010957 A2 BR 112014010957A2
Authority
BR
Brazil
Prior art keywords
substituted
receptor ligands
carboxamide derivatives
group containing
moiety
Prior art date
Application number
BR112014010957A
Other languages
Portuguese (pt)
Inventor
Lesch Bernhard
John Saunders Derek
Bahrenberg Gregor
Stockhausen Hannelore
Lee Jeewoo
Kim Myeong-Seop
Damann Nils
Frank-Foltyn Robert
Christoph Thomas
Kim Yong-Soo
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112014010957A2 publication Critical patent/BR112014010957A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

resumo patente de invenção: "derivados de ureia e carboxamida com base em pirazolila substituída transportando uma porção de fenila substituída por um grupo contendo n como ligantes de receptor de vaniloide". a invenção refere-se aos derivados de ureia e carboxamida com base em pirazolila substituída transportando uma porção de fenila substituída por um grupo contendo n como ligantes de receptor de vaniloide, às composições farmacêuticas contendo estes compostos e também a estes compostos para uso no tratamento e/ou profilaxia de dor e outras doenças e/ou distúrbios. 21210660v1 1/1 21210660v1Summary Patent: "Substituted pyrazolyl-based urea and carboxamide derivatives carrying a phenyl moiety substituted with a group containing n as vanyloid receptor ligands". The invention relates to substituted pyrazolyl-based urea and carboxamide derivatives carrying a group-substituted phenyl moiety containing vanyloid receptor ligands, pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and / or prophylaxis of pain and other diseases and / or disorders. 21210660v1 1/1 21210660v1

BR112014010957A 2011-11-09 2012-11-08 substituted pyrazolyl-based urea and carboxamide derivatives carrying a moiety of phenyl substituted by a group containing n as vanyloid receptor ligands BR112014010957A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11008913 2011-11-09
PCT/EP2012/072141 WO2013068462A1 (en) 2011-11-09 2012-11-08 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands

Publications (1)

Publication Number Publication Date
BR112014010957A2 true BR112014010957A2 (en) 2017-06-06

Family

ID=47143123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010957A BR112014010957A2 (en) 2011-11-09 2012-11-08 substituted pyrazolyl-based urea and carboxamide derivatives carrying a moiety of phenyl substituted by a group containing n as vanyloid receptor ligands

Country Status (13)

Country Link
EP (1) EP2776399A1 (en)
JP (1) JP2014532742A (en)
KR (1) KR20140096351A (en)
CN (1) CN103906736A (en)
AR (1) AR088701A1 (en)
AU (1) AU2012334066A1 (en)
BR (1) BR112014010957A2 (en)
CA (1) CA2854935A1 (en)
HK (1) HK1202116A1 (en)
IN (1) IN2014KN00847A (en)
MX (1) MX2014005611A (en)
TW (1) TW201326134A (en)
WO (1) WO2013068462A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108593B (en) * 2014-11-24 2020-03-24 美迪福伦Dbt有限公司 Substituted oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II
CN114920697A (en) * 2022-05-16 2022-08-19 河南应用技术职业学院 Heterocyclic group substituted indan propionamide compound and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020447A4 (en) * 1997-09-11 2000-11-15 Nissan Chemical Ind Ltd Pyrazole compounds and plant disease control agent
BRPI0618417A2 (en) * 2005-10-19 2012-07-31 Gruenenthal Chemie new vanillary receptor ligands and their use to produce drugs
WO2008073825A1 (en) * 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
JP2010523727A (en) * 2007-04-16 2010-07-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Vanilloid receptor ligands and their use in the manufacture of medicaments
DE102007018151A1 (en) * 2007-04-16 2008-10-23 Günenthal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
US8592471B2 (en) * 2009-05-07 2013-11-26 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
WO2010127855A1 (en) 2009-05-07 2010-11-11 Grünenthal GmbH Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
WO2013068463A1 (en) * 2011-11-09 2013-05-16 Grünenthal GmbH Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands

Also Published As

Publication number Publication date
MX2014005611A (en) 2014-07-30
JP2014532742A (en) 2014-12-08
KR20140096351A (en) 2014-08-05
EP2776399A1 (en) 2014-09-17
HK1202116A1 (en) 2015-09-18
CN103906736A (en) 2014-07-02
AR088701A1 (en) 2014-06-25
TW201326134A (en) 2013-07-01
AU2012334066A1 (en) 2014-05-22
WO2013068462A1 (en) 2013-05-16
IN2014KN00847A (en) 2015-10-02
CA2854935A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BR112014001880A2 (en) substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanyloid receptor ligands
BR112014001908A2 (en) substituted heterocyclic aza derivatives
BR112013004766A2 (en) Substituted 2-amino-quinoline-3-carboxamides as kcnq2 / 3 modulators
EA200970967A1 (en) OXADIAZOLE-SUBSTITUTED DERIVATIVES INDASOLS FOR APPLICATION AS AGONISTS SPHINGOZIN 1-PHOSPHATE (SIP)
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
EA201200176A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EA201391029A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
EA201591727A1 (en) BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS
BR112015019720A2 (en) 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl) -amide inhibitors of cathepsin c
BR112015000578A2 (en) complement pathway modulators and their uses
EA201391644A1 (en) PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS FOR THEIR RECEPTION AND APPLICATION
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
EA201070327A1 (en) CATECHOLAMINE DERIVATIVES AND THEIR DEVICES
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
EA201590562A1 (en) БЕНЗАМИДЫ
BR112014012459A2 (en) 2h-indazoles as ep2 receptor antagonists
MA32943B1 (en) Biperiden spiro-pyrrolidone and biperidenone are substituted, prepared and used in treatment
CY1116234T1 (en) Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2 / 3 conformers
BR112013004721A2 (en) "Substituted quinoline-3-carboxamides as kcnq2 / 3 modulators"
MA32945B1 (en) Tetrahydroperan spiro-pyrolidinone substituted biperidenone, its preparation and use in treatment
EA201490573A1 (en) CONTAINING BENZOTHIAZOLONE
BR112014001714A2 (en) substituted bicyclic aromatic carboxamide and urea derivatives as vanyloid receptor ligands
BR112014006675A2 (en) substituted methanesulfonamide derivatives as vanyloid receptor ligands
CY1116158T1 (en) Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.